Kynam Capital Reduces Stake in CG Oncology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CGON?
Source: NASDAQ.COM
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4, with an estimated transaction value of $43.84 million, reflecting a cautious market sentiment regarding the company's future performance.
- Position Value Change: Post-sale, Kynam's stake decreased to 945,830 shares, valued at $39.27 million at quarter-end, indicating a net position change of $41.50 million due to trading activity and price fluctuations.
- Company Financial Health: CG Oncology focuses on innovative therapies for bladder cancer, generating only about $4 million in annual revenue, yet boasting over $740 million in cash reserves, providing a runway into 2029 and demonstrating financial resilience.
- Market Outlook and Risks: Despite CG Oncology's stock rising over 130% in the past year, its future performance heavily relies on upcoming clinical trial data, necessitating investor caution regarding the high expectations priced into the stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGON
Wall Street analysts forecast CGON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 65.860
Low
65.00
Averages
79.73
High
108.00
Current: 65.860
Low
65.00
Averages
79.73
High
108.00
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kynam Capital Reduces Stake in CG Oncology
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4 2026 for an estimated $43.84 million, indicating a cautious outlook on the company's future performance.
- Ownership Percentage Change: Following the sale, CG Oncology now represents 2.51% of Kynam's holdings, down from 6.0% in the previous quarter, reflecting a decline in investor confidence in the stock.
- Company Financial Overview: CG Oncology has a market capitalization of $5.5 billion, with annual revenue of only $4 million and a net loss of $160.1 million, highlighting its ongoing clinical-stage status and profitability challenges.
- Future Growth Potential: Despite these challenges, CG Oncology holds over $740 million in cash, providing runway until 2029, with upcoming Phase 3 data expected to significantly impact stock performance and investor sentiment.
See More
Kynam Capital Reduces Stake in CG Oncology
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4, with an estimated transaction value of $43.84 million, reflecting a cautious market sentiment regarding the company's future performance.
- Position Value Change: Post-sale, Kynam's stake decreased to 945,830 shares, valued at $39.27 million at quarter-end, indicating a net position change of $41.50 million due to trading activity and price fluctuations.
- Company Financial Health: CG Oncology focuses on innovative therapies for bladder cancer, generating only about $4 million in annual revenue, yet boasting over $740 million in cash reserves, providing a runway into 2029 and demonstrating financial resilience.
- Market Outlook and Risks: Despite CG Oncology's stock rising over 130% in the past year, its future performance heavily relies on upcoming clinical trial data, necessitating investor caution regarding the high expectations priced into the stock.
See More
Royal Caribbean Group Sees Surge in Options Trading Volume
- Surge in Options Volume: Royal Caribbean Group (RCL) recorded an options trading volume of 31,614 contracts today, equivalent to approximately 3.2 million shares, which is 134.7% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Demand Options: Notably, the $350 strike call option expiring on April 17, 2026, saw 8,036 contracts traded today, representing about 803,600 underlying shares of RCL, suggesting investor expectations for future price increases.
- Surgery Partners Options Activity: Concurrently, Surgery Partners Inc (SGRY) experienced an options trading volume of 20,059 contracts today, equivalent to approximately 2.0 million shares, which is 97.5% of its average daily trading volume over the past month, highlighting the stock's market activity.
- Put Option Demand: Specifically, the $15 strike put option expiring on June 18, 2026, recorded a trading volume of 10,000 contracts today, representing around 1.0 million underlying shares of SGRY, reflecting investor concerns about potential declines in the stock's future performance.
See More
CG Oncology Reports FY Earnings with Significant Revenue Growth
- Earnings Highlights: CG Oncology's FY GAAP EPS of -$2.08 beats expectations by $0.09, indicating some progress in cost management despite still being in a loss position.
- Revenue Surge: The company reported FY revenue of $4.04M, a remarkable 254.4% year-over-year increase, surpassing market expectations by $1.24M, showcasing strong demand and sales capability for its products.
- Clinical Trial Progress: At the 44th Annual J.P. Morgan Healthcare Conference, CG Oncology presented advancements in its lead asset Cretostimogene, having completed recruitment earlier than expected, which may expedite its market launch.
- Positive Market Reaction: Following the acceleration of its key asset's clinical trial, CG Oncology's stock price rose, reflecting increased investor confidence in the company's future growth potential.
See More
CG Oncology Reports 2025 Financial Results and Clinical Progress
- Clinical Trial Progress: CG Oncology anticipates releasing topline data from the Phase 3 PIVOT-006 trial evaluating cretostimogene as an adjuvant therapy for intermediate-risk NMIBC in the first half of 2026, highlighting the company's innovative potential in this field.
- Strong Financial Position: As of February 26, 2026, the company reported approximately $903 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into the first half of 2029, demonstrating robust financial strength and ongoing R&D capabilities.
- Increased R&D Expenses: R&D expenses for Q4 2025 reached $30 million, up from $26.8 million in the prior year, primarily due to rising clinical trial costs and personnel expenses, reflecting the company's commitment to new drug development.
- Board Enhancement: In November 2025, CG Oncology appointed Christina Rossi to its board, who brings extensive experience in the life sciences sector, expected to drive the company's strategic execution in drug commercialization and market outreach.
See More
CG Oncology Inc. Reports $903 Million in Cash and Marketable Securities to Support Operations Through First Half of 2029
Financial Overview: C Oncology Inc. has reported a cash position of $903 million, which includes cash equivalents and marketable securities.
Operational Funding: The available funds are deemed sufficient to support operations into the first half of 2029.
See More
Kynam Capital Reduces Stake in CG Oncology
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4 2026 for an estimated $43.84 million, indicating a cautious outlook on the company's future performance.
- Ownership Percentage Change: Following the sale, CG Oncology now represents 2.51% of Kynam's holdings, down from 6.0% in the previous quarter, reflecting a decline in investor confidence in the stock.
- Company Financial Overview: CG Oncology has a market capitalization of $5.5 billion, with annual revenue of only $4 million and a net loss of $160.1 million, highlighting its ongoing clinical-stage status and profitability challenges.
- Future Growth Potential: Despite these challenges, CG Oncology holds over $740 million in cash, providing runway until 2029, with upcoming Phase 3 data expected to significantly impact stock performance and investor sentiment.
See More
Kynam Capital Reduces Stake in CG Oncology
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4, with an estimated transaction value of $43.84 million, reflecting a cautious market sentiment regarding the company's future performance.
- Position Value Change: Post-sale, Kynam's stake decreased to 945,830 shares, valued at $39.27 million at quarter-end, indicating a net position change of $41.50 million due to trading activity and price fluctuations.
- Company Financial Health: CG Oncology focuses on innovative therapies for bladder cancer, generating only about $4 million in annual revenue, yet boasting over $740 million in cash reserves, providing a runway into 2029 and demonstrating financial resilience.
- Market Outlook and Risks: Despite CG Oncology's stock rising over 130% in the past year, its future performance heavily relies on upcoming clinical trial data, necessitating investor caution regarding the high expectations priced into the stock.
See More
Royal Caribbean Group Sees Surge in Options Trading Volume
- Surge in Options Volume: Royal Caribbean Group (RCL) recorded an options trading volume of 31,614 contracts today, equivalent to approximately 3.2 million shares, which is 134.7% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Demand Options: Notably, the $350 strike call option expiring on April 17, 2026, saw 8,036 contracts traded today, representing about 803,600 underlying shares of RCL, suggesting investor expectations for future price increases.
- Surgery Partners Options Activity: Concurrently, Surgery Partners Inc (SGRY) experienced an options trading volume of 20,059 contracts today, equivalent to approximately 2.0 million shares, which is 97.5% of its average daily trading volume over the past month, highlighting the stock's market activity.
- Put Option Demand: Specifically, the $15 strike put option expiring on June 18, 2026, recorded a trading volume of 10,000 contracts today, representing around 1.0 million underlying shares of SGRY, reflecting investor concerns about potential declines in the stock's future performance.
See More
CG Oncology Reports FY Earnings with Significant Revenue Growth
- Earnings Highlights: CG Oncology's FY GAAP EPS of -$2.08 beats expectations by $0.09, indicating some progress in cost management despite still being in a loss position.
- Revenue Surge: The company reported FY revenue of $4.04M, a remarkable 254.4% year-over-year increase, surpassing market expectations by $1.24M, showcasing strong demand and sales capability for its products.
- Clinical Trial Progress: At the 44th Annual J.P. Morgan Healthcare Conference, CG Oncology presented advancements in its lead asset Cretostimogene, having completed recruitment earlier than expected, which may expedite its market launch.
- Positive Market Reaction: Following the acceleration of its key asset's clinical trial, CG Oncology's stock price rose, reflecting increased investor confidence in the company's future growth potential.
See More
CG Oncology Reports 2025 Financial Results and Clinical Progress
- Clinical Trial Progress: CG Oncology anticipates releasing topline data from the Phase 3 PIVOT-006 trial evaluating cretostimogene as an adjuvant therapy for intermediate-risk NMIBC in the first half of 2026, highlighting the company's innovative potential in this field.
- Strong Financial Position: As of February 26, 2026, the company reported approximately $903 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into the first half of 2029, demonstrating robust financial strength and ongoing R&D capabilities.
- Increased R&D Expenses: R&D expenses for Q4 2025 reached $30 million, up from $26.8 million in the prior year, primarily due to rising clinical trial costs and personnel expenses, reflecting the company's commitment to new drug development.
- Board Enhancement: In November 2025, CG Oncology appointed Christina Rossi to its board, who brings extensive experience in the life sciences sector, expected to drive the company's strategic execution in drug commercialization and market outreach.
See More
CG Oncology Inc. Reports $903 Million in Cash and Marketable Securities to Support Operations Through First Half of 2029
Financial Overview: C Oncology Inc. has reported a cash position of $903 million, which includes cash equivalents and marketable securities.
Operational Funding: The available funds are deemed sufficient to support operations into the first half of 2029.
See More
